The global CAR T-cell therapy market revenue was around US$ 1.9 billion in 2022 and is estimated to reach US$ 5.9 billion by 2031, growing at a compound annual growth rate (CAGR) of 13.5% during the forecast period from 2023 to 2031.
Chimeric antigen receptor (CAR)-T cell therapy is a kind of gene cell therapy in which the T cells are utilized to kill the cancer cells. There are generally three steps involved in CAR T cell therapy which include: the engineering of T cells, infusing the CAR T cells, and collecting of T cells, in the human body.
Market Driving Factors
Increasing awareness and surge in approval of novel medicines drive the market expansion. This is mainly due to the CAR-T cells generating "armored CARs" that co-express pro-inflammatory cytokines like (Interleukin) IL-15 or IL-12. In addition, it raises CAR T-cell proliferation and persistence at the beginning of tumor-mediated immunosuppression.
Increasing product approvals associated with chimeric antigen receptor (CAR)-T cell therapy is estimated to boost the market growth. For instance, in February 2022, the Janssen Pharmaceutical Companies of Johnson & Johnson noted the U.S.FDA approved CARVYKTI for the treatment of adults suffering from relapsed or refractory multiple myeloma (RRMM) after four or more previous lines of therapy, which includes a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Serious adverse effects with CAR T-cell therapy include infections and a mass death of B cells that produce antibodies, similar to those seen with cancer treatments. This factor is estimated to hamper the market.
Regional Analysis
North America dominated the market in terms of the growth rate. This is mainly attributed to the surged cancer cases and increased emergence of the biotechnological sector. Furthermore, the surge in the number of cancer cases raised the market demand for cancer therapies in the region. Moreover, the existence of key players in the region such as Bellicum Pharmaceuticals Inc., Amgen Inc., Caribou Biosciences Inc., and Bluebird Bio concentrated on expanding their global presence in the market.
Asia-Pacific is estimated to dominate the market in terms of the highest growth rate during the projection period. This is due to the large pool of patient population seeking cancer treatment, the surging prevalence of cancer, investments by the key players, rising government spending on healthcare, and increasing disposable income of the population leading to enhanced access to cancer treatment.
Segmentation Insights
Indication Insight
The acute lymphocytic leukemia segment is predicted to dominate the market in terms of growth rate. This is primarily due to the surge in awareness of CAR-T cell therapeutics for treating acute leukemia and the expected introduction of these drugs for treating acute lymphoblastic leukemia involves blood cell cancer testing. Furthermore, the surge in Acute Lymphoblastic Leukemia (ALL) and initiatives undertaken by private and public organizations also contribute to boosting the segment growth.
End User Insight
The hospital segment dominates the market in terms of the largest revenue share. This is mainly due to the hospitalization for cancer therapy. The rise in the application of CAR T-cell therapy in cancer treatment also stimulates segment growth. Moreover, the increase in the number of cancer patients seeking treatment in hospitals also propels the market.
The cancer treatment center segment dominates the market in terms of the highest rate. This is primarily due to the availability of a vast range of treatment options and the increase in cancer centers in some developing nations. Moreover, the increasing global oncology load caused by a surge in alcohol and tobacco consumption boosts the segment growth.
Prominent Companies
Segmentation Outline
The global CAR T-cell therapy market segmentation focuses on the Drug Type, Indication, End User, and Region.
By Drug Type
By Indication
By End User
By Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL CAR T-CELL THERAPY MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY: CAR T-CELL THERAPY MARKET
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS
4 GLOBAL CAR T-CELL THERAPY MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE
5 GLOBAL CAR T-CELL THERAPY MARKET, BY DRUG TYPE
5.1 OVERVIEW
5.2 AXICABTAGENE CILOLEUCEL
5.3 TISAGENLECLEUCEL
5.4 BREXUCABTAGENE AUTOLEUCEL
5.5 OTHERS
6 GLOBAL CAR T-CELL THERAPY MARKET, BY INDICATION
6.1 OVERVIEW
6.2 LYMPHOMA
6.3 ACUTE LYMPHOCYTIC LEUKEMIA
6.4 OTHERS
7 GLOBAL CAR T-CELL THERAPY MARKET, BY END USER
7.1 OVERVIEW
7.2 HOSPITALS
7.3 CANCER TREATMENT CENTERS
8 GLOBAL CAR T-CELL THERAPY MARKET, BY GEOGRAPHY
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA MARKET SNAPSHOT
8.2.2 U.S.
8.2.3 CANADA
8.2.4 MEXICO
8.3 EUROPE
8.3.1 EUROPE MARKET SNAPSHOT
8.3.2 WESTERN EUROPE
8.3.2.1 THE UK
8.3.2.2 GERMANY
8.3.2.3 FRANCE
8.3.2.4 ITALY
8.3.2.5 SPAIN
8.3.2.6 REST OF WESTERN EUROPE
8.3.3 EASTERN EUROPE
8.3.3.1 POLAND
8.3.3.2 RUSSIA
8.3.3.3 REST OF EASTERN EUROPE
8.4 ASIA PACIFIC
8.4.1 ASIA PACIFIC MARKET SNAPSHOT
8.4.2 CHINA
8.4.3 JAPAN
8.4.4 INDIA
8.4.5 AUSTRALIA & NEW ZEALAND
8.4.6 ASEAN
8.4.7 REST OF ASIA PACIFIC
8.5 MIDDLE EAST & AFRICA
8.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
8.5.2 UAE
8.5.3 SAUDI ARABIA
8.5.4 SOUTH AFRICA
8.5.5 REST OF MEA
8.6 SOUTH AMERICA
8.6.1 SOUTH AMERICA MARKET SNAPSHOT
8.6.2 BRAZIL
8.6.3 ARGENTINA
8.6.4 REST OF SOUTH AMERICA
9 GLOBAL CAR T-CELL THERAPY MARKET COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPANY MARKET RANKING
9.3 KEY DEVELOPMENT STRATEGIES
9.4 COMPETITIVE DASHBOARD
9.5 PRODUCT MAPPING
9.6 TOP PLAYER POSITIONING, 2022
9.7 COMPETITIVE HEATMAP
9.8 TOP WINNING STRATEGIES
10 COMPANY PROFILES
10.1 CELGENE CORPORATION
10.1.1 OVERVIEW
10.1.2 FINANCIAL PERFORMANCE
10.1.3 PRODUCT OUTLOOK
10.1.4 KEY DEVELOPMENTS
10.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.2 GILEAD SCIENCES INC
10.2.1 OVERVIEW
10.2.2 FINANCIAL PERFORMANCE
10.2.3 PRODUCT OUTLOOK
10.2.4 KEY DEVELOPMENTS
10.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.3 CELYAD ONCOLOGY
10.3.1 OVERVIEW
10.3.2 FINANCIAL PERFORMANCE
10.3.3 PRODUCT OUTLOOK
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.4 PFIZER INC
10.4.1 OVERVIEW
10.4.2 FINANCIAL PERFORMANCE
10.4.3 PRODUCT OUTLOOK
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.5 AUTOLUS THERAPEUTICS
10.5.1 OVERVIEW
10.5.2 FINANCIAL PERFORMANCE
10.5.3 PRODUCT OUTLOOK
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.6 SORRENTO THERAPEUTICS INC
10.6.1 OVERVIEW
10.6.2 FINANCIAL PERFORMANCE
10.6.3 PRODUCT OUTLOOK
10.6.4 KEY DEVELOPMENTS
10.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.7 BRISTOL-MYERS SQUIBB
10.7.1 OVERVIEW
10.7.2 FINANCIAL PERFORMANCE
10.7.3 PRODUCT OUTLOOK
10.7.4 KEY DEVELOPMENTS
10.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.8 CARTESIAN THERAPEUTICS INC
10.8.1 OVERVIEW
10.8.2 FINANCIAL PERFORMANCE
10.8.3 PRODUCT OUTLOOK
10.8.4 KEY DEVELOPMENTS
10.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.9 CARIBOU BIOSCIENCES INC
10.9.1 OVERVIEW
10.9.2 FINANCIAL PERFORMANCE
10.9.3 PRODUCT OUTLOOK
10.9.4 KEY DEVELOPMENTS
10.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.10 MERCK & CO INC
10.10.1 OVERVIEW
10.10.2 FINANCIAL PERFORMANCE
10.10.3 PRODUCT OUTLOOK
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.11 NOVARTIS AG
10.11.1 OVERVIEW
10.11.2 FINANCIAL PERFORMANCE
10.11.3 PRODUCT OUTLOOK
10.11.4 KEY DEVELOPMENTS
10.11.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.12 CELLECTIS
10.12.1 OVERVIEW
10.12.2 FINANCIAL PERFORMANCE
10.12.3 PRODUCT OUTLOOK
10.12.4 KEY DEVELOPMENTS
10.12.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.13 MILTENYI BIOTECH
10.13.1 OVERVIEW
10.13.2 FINANCIAL PERFORMANCE
10.13.3 PRODUCT OUTLOOK
10.13.4 KEY DEVELOPMENTS
10.13.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.14 JUNO THERAPEUTICS INC
10.14.1 OVERVIEW
10.14.2 FINANCIAL PERFORMANCE
10.14.3 PRODUCT OUTLOOK
10.14.4 KEY DEVELOPMENTS
10.14.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.15 INTELLIA THERAPEUTICS
10.15.1 OVERVIEW
10.15.2 FINANCIAL PERFORMANCE
10.15.3 PRODUCT OUTLOOK
10.15.4 KEY DEVELOPMENTS
10.15.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.16 BLUEBIRD BIO INC
10.16.1 OVERVIEW
10.16.2 FINANCIAL PERFORMANCE
10.16.3 PRODUCT OUTLOOK
10.16.4 KEY DEVELOPMENTS
10.16.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved